Ryohei Kozaki 研究室（名古屋大学）

AI 要約（直近 5 年の研究成果）

要約はまだ生成されていません。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（17 件）

[2026] Supplementary Figure S6 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
DOI: https://doi.org/10.1158/0008-5472.32675367
[2026] Data from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
DOI: https://doi.org/10.1158/0008-5472.c.8536806
[2026] Supplementary Figure S3 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
DOI: https://doi.org/10.1158/0008-5472.32675376
[2026] Supplementary Table S1 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
DOI: https://doi.org/10.1158/0008-5472.32675364
[2026] Supplementary Figure S5 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
DOI: https://doi.org/10.1158/0008-5472.32675370
[2026] Supplementary Figure S4 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
DOI: https://doi.org/10.1158/0008-5472.32675373
[2026] Supplementary Figure S2 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
DOI: https://doi.org/10.1158/0008-5472.32675379
[2026] Supplementary Figure S1 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
DOI: https://doi.org/10.1158/0008-5472.32675382
[2026] Abstract 7292: Hypoxia-driven HIF-1α/YAP-AXL signaling drives adaptive resistance to TKIs in NSCLC
DOI: https://doi.org/10.1158/1538-7445.am2026-7292
[2026] A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
DOI: https://doi.org/10.1158/0008-5472.can-25-2848

続きを表示（残り 7 件）

[2026] Release of phosphate and phosphonate from phenylphosphonate-modified zirconium phosphate in biomimetic solutions
DOI: https://doi.org/10.2109/jcersj2.25147
[2025] Abstract 5617: Development of an initial triple combination therapy targeting EGFR, AXL, and FGFR for EGFR-mutated non-small cell lung cancer
DOI: https://doi.org/10.1158/1538-7445.am2025-5617
[2024] Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
DOI: https://doi.org/10.1016/j.canlet.2024.217124
[2023] ONO-7018, a First-in-Class MALT1 Inhibitor, Provides Novel Therapeutic Strategies for B Cell Malignancies: Overcoming BTK Inhibitor Acquired Resistance and Enhancing the Antitumor Effect of BTK Inhibitors
DOI: https://doi.org/10.1182/blood-2023-185997
[2023] Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton’s tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics
DOI: https://doi.org/10.1371/journal.pone.0282166
[2021] AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia
DOI: https://doi.org/10.3324/haematol.2021.278369
[2021] Organic modification of layered zirconium phosphate/phosphonate for controlled release of therapeutic inorganic ions
DOI: https://doi.org/10.1080/14686996.2021.1993728

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（17 件）

科研費（0 件）

所属学会・役職（0 件）